Introduction {#s1}
============

Celiac disease (CeD) is a systemic disorder with an increasing worldwide prevalence of \~1% (Di Sabatino and Corazza, [@B11]; Catassi et al., [@B7]). In CeD, the immune-mediated destruction of small intestinal villous architecture is triggered by dietary gluten (Reilly et al., [@B42]).

Rationale of the Study
----------------------

Although the value of intestinal biopsy at diagnosis is beyond dispute (Bai et al., [@B2]; Rubio-Tapia et al., [@B43]; Ludvigsson et al., [@B33]), the role of follow-up biopsy is a matter of controversy (Pekki et al., [@B40]). While the restitution of intestinal villi is expected on a strict gluten-free diet, the mucosa fails to restore entirely in a considerable fraction of patients (Szakacs et al., [@B48]). Recent guidelines recommend a follow-up biopsy if signs and symptoms persist or relapse despite strict adherence to a gluten-free diet (Bai et al., [@B2]; Rubio-Tapia et al., [@B43]; Ludvigsson et al., [@B33]). However, reports proposed that neither the resolution of symptoms (Bardella et al., [@B3]; Biagi et al., [@B4]; Fang et al., [@B14]; Mahadev et al., [@B36]) nor a strict dietary adherence (Szakacs et al., [@B48]) guarantees mucosal recovery (MR). One might expect that CeD patients with persistent villous atrophy (PVA) experience a less favorable disease course than those achieving MR (Haines et al., [@B18]), although convincing evidence is lacking. Yet, achieving MR has remained a desirable goal in CeD. The importance of the topic roots in the burden imposed by the endoscopic procedures and duodenal histological sampling as well as in the subsequent clinical decisions made upon follow-up histology.

Objective of the Study
----------------------

With this systematic review, we aimed to be the first who systematically collect all available evidence on the impact of follow-up histology (MR vs. PVA) on disease characteristics and clinical course of CeD.

Research Question
-----------------

Are CeD patients who have not achieved MR exposed to adverse clinical outcomes more frequently than those patients who have achieved MR?

Methods {#s2}
=======

Study Design
------------

This systematic review was reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses 2009 (Moher et al., [@B38]).

Participants and Exposure
-------------------------

Participants of this systematic review include CeD patients subjected to a gluten-free diet. The exposure of interest is the follow-up duodenal histology assessed as either MR or PVA.

Systematic Review Protocol
--------------------------

The study protocol was registered *a priori* on PROSPERO under CRD42017069815.

Search Strategy
---------------

We performed a systematic literature search in MEDLINE (via PubMed), Embase, Cochrane Controlled Register of Trials (CENTRAL), Web of Science, Scopus, WHO Global Index Medicus, and [ClinicalTrials.gov](http://ClinicalTrials.gov) from inception up to 14th September 2019 for relevant articles. Free-text terms and Medical Subject Headings were combined into a query, as follows: *celiac AND ("mucosal recovery" OR "mucosal healing" OR "mucosal atrophy" OR "intestinal atrophy" OR "duodenal atrophy" OR "villous atrophy" OR "persistent mucosal damage" OR "follow-up biopsy" OR "follow-up duodenal biopsy" OR "follow-up intestinal biopsy" OR "follow-up small intestinal biopsy" OR "follow-up histology" OR "repeated biopsy" OR "repeated histology" OR "control biopsy" OR "control histology")*. No filters were imposed upon the search.

Relevant cited articles were explored by reviewing the reference lists of included papers. Citing articles were identified with Google Scholar.

Data Sources, Study Selection, and Data Extraction
--------------------------------------------------

### Eligibility Criteria

Eligible papers discussed CeD patients subjected to a gluten-free diet with an available record of duodenal follow-up histology, and reported on disease and patients characteristics by follow-up histology. Analytical and descriptive full-text articles or conference abstracts but not case studies were included without language restriction to reduce publication bias.

In our previous meta-analysis, we experienced a substantial variance in the definition of MR across studies (Szakacs et al., [@B48]). In this systematic review, we defined MR as the resolution of villous atrophy at follow-up biopsy assessed as "non-atrophic" histology based on crypt height:villous depth ratio, Marsh grades 0-2, Marsh-Oberhuber grades 0-2, or Corazza-Villanacci grade A; while PVA was defined as "atrophic" histology, Marsh grade 3, Marsh-Oberhuber grade 3, or Corazza-Villanacci grade B1-B2 (Marsh, [@B37]; Oberhuber et al., [@B39]; Corazza and Villanacci, [@B9]).

Disease and patients characteristics included signs and symptoms, vitamin and mineral levels, anemia, body mass index, metabolic bone disease, malignant tumors and other co-morbid conditions, and long-term mortality.

### Selection and Data Collection

Records were combined in a reference manager software (EndNote X7.4, Clarivate Analytics, Philadelphia, PA, the USA) to remove duplicates and overlapping database content. Then, the standard three-step selection was performed by title, abstract and full-texts. Each step was carried out by two investigators in duplicate. Discrepancies were resolved by third-party arbitration. K-statistics was used to measure the agreement between the investigators after each step.

Numeric and text data were extracted by two investigators onto a pre-defined Excel sheet, discrepancies were resolved by consensus. Although we contacted the authors of original studies for further raw data via email, we discarded these data from the systematic review when we realized that the material is ineligible for meta-analysis due to several reasons (as detailed later).

### Design of the Studies Included and Quality Assessment

First, the design of the included papers was identified. Then, quality indicators were chosen based on the Quality in Prognostic Studies tool (Hayden et al., [@B21]), as follows:

-   way of recruitment,

-   diagnosis of CeD (only biopsy-verified cases or not),

-   the recency of diagnosis (newly diagnosed patients or treated patients were included),

-   representativeness of study population to the general CeD population (based on the inclusion and exclusion criteria of the individual studies),

-   timing of follow-up biopsy (taken prospectively after enrolment or earlier),

-   time elapsed between the diagnosis of CeD and the follow-up biopsy, and that between the follow-up biopsy and the measurement of outcomes,

-   definition of PVA (histological classification),

-   biopsy sampling site,

-   timing of outcome assessment (prospectively after enrolment or earlier),

-   definitions of outcomes (with cut-off values if applicable),

-   blinding,

-   adherence to a gluten-free diet (strict or not), and

-   statistical considerations (the analysis directly compared the clinical characteristics by MR and PVA or not and the analysis was adjusted for reasonable confounding factors or not).

Results {#s3}
=======

Study Selection and Characteristics
-----------------------------------

After careful search and selection ([Figure 1](#F1){ref-type="fig"}), 31 papers were included in the systematic review (Souroujon et al., [@B46]; Thornquist et al., [@B50]; Valdimarsson et al., [@B52]; Walters et al., [@B53]; Kemppainen et al., [@B23]; Selby et al., [@B45]; Ciacci et al., [@B8]; Bardella et al., [@B3]; Cammarota et al., [@B5]; Kaukinen et al., [@B22]; Carroccio et al., [@B6]; Dickey et al., [@B12]; Koskinen et al., [@B24]; Rubio-Tapia et al., [@B44]; Tuire et al., [@B51]; Lebwohl et al., [@B27],[@B28], [@B29], [@B26],[@B30]; Ghazzawi et al., [@B16]; Pekki et al., [@B41], [@B40]; Cornell et al., [@B10]; Haere et al., [@B17]; Fang et al., [@B14]; Leonard et al., [@B32]; Mahadev et al., [@B36]; Emilsson et al., [@B13]; Kurien et al., [@B25]; Ludvigsson et al., [@B34]) ([Table 1](#T1){ref-type="table"}). Cohen\'s κ representing inter-reviewer agreement was 0.72 (substantial), 0.79 (substantial), and 0.92 (almost perfect) for selection by title, abstract, and full-text; respectively.

![Flowchart of the search and selection process.](fphys-10-01408-g0001){#F1}

###### 

Characteristics of the studies included.

  **Study**                                                                                                                                              **Setting**                                                     **Study population and design**                                                                   **Definition of villous atrophy and sampling site**                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------- ----- ----- ---------------------------------------- ---------------------------------------- --------------------------------------------
  Bardella et al. ([@B3])                                                                                                                                Italy (single-center)                                           Consecutive pts                                                                                   Adults and children                                   Yes   No    No                                       No                                       Marsh-Oberhuber 3~a−c~, duodenum
  Cammarota et al. ([@B5])                                                                                                                               Italy (2-center)                                                Consecutive pts                                                                                   Adults                                                Yes   Yes   No                                       Yes                                      Marsh-Oberhuber 3~a−c~, duodenum
  Carroccio et al. ([@B6])                                                                                                                               Italy (single-center)                                           Consecutive symptomatic pts and randomly selected matched asymptomatic pts                        Adults                                                Yes   Yes   No                                       Yes                                      Marsh-Oberhuber 3~a−c~, duodenum
  Ciacci et al. ([@B8])                                                                                                                                  Italy (single-center)                                           Consecutive pts                                                                                   Adults                                                Yes   Yes   No                                       No                                       Marsh 3, small intestine
  Cornell et al. ([@B10])                                                                                                                                Poland (single-center)                                          Consecutive volunteer                                                                             Adults                                                Yes   Yes   No                                       Yes                                      Marsh 3, duodenum
  Dickey et al. ([@B12])                                                                                                                                 Northern Ireland (single-center)                                Consecutive pts                                                                                   Adults                                                Yes   Yes   No                                       Yes                                      Marsh 3, duodenum
  Fang et al. ([@B14])                                                                                                                                   The USA (Single-center)                                         Consecutive pts                                                                                   Adults                                                (?)   No    No                                       No                                       Corazza-Villanacci B~1−2~, duodenum
  Ghazzawi et al. ([@B16])                                                                                                                               The USA (single-center)                                         Consecutive pts                                                                                   Children                                              Yes   Yes   No                                       No                                       Marsh 3, small intestine
  Haere et al. ([@B17])                                                                                                                                  Norway (single-center)                                          Consecutive pts by invitation                                                                     Adults                                                Yes   Yes   No                                       Yes                                      Marsh-Oberhuber 3~a−c~, duodenum
  Kaukinen et al. ([@B22])                                                                                                                               Finland (single-center)                                         Consecutive pts with persistent villous atrophy and randomly selected pts with mucosal recovery   Adults                                                (?)   Yes   No                                       No                                       Vh/Cr\<2, duodenum, jejunum
  Kemppainen et al. ([@B23])                                                                                                                             Finland (single-center)                                         *Post-hoc* analysis of a randomized trial                                                         Adults                                                Yes   Yes   No                                       No                                       Not reported ("atrophic"), duodenum
  Koskinen et al. ([@B24])                                                                                                                               Finland (single-center)                                         Consecutive pts                                                                                   Adults and children                                   Yes   No    Yes/No[^b^](#TN2){ref-type="table-fn"}   Yes                                      Vh/Cr\<2, jejunum
  Lebwohl et al. ([@B27],[@B28]); Lebwohl et al. ([@B29], [@B26],[@B30]), Emilsson et al. ([@B13]), Ludvigsson et al. ([@B34]), Kurien et al. ([@B25])   Sweden (28-center)                                              Consecutive pts (nationwide sample)                                                               Adults and children                                   Yes   Yes   No                                       No                                       Marsh 3, small intestine
  Leonard et al. ([@B32])                                                                                                                                Italy (2-center)                                                Consecutive pts                                                                                   Children                                              Yes   Yes   No                                       No                                       Marsh-Oberhuber 3~a−c~, duodenum
  Mahadev et al. ([@B36])                                                                                                                                North-America, Ireland, UK, Norway, and Finland (multicenter)   *Post-hoc* analysis of a randomized trial                                                         Adults                                                (?)   No    No                                       No                                       Vh/Cr≤2, duodenum
  Pekki et al. ([@B41])                                                                                                                                  Finland (single-center)                                         Consecutive pts                                                                                   Adults                                                Yes   Yes   (?)                                      Yes                                      Vh/Cr\<2, duodenum
  Pekki et al. ([@B40])                                                                                                                                  Finland (single-center)                                         Consecutive volunteers                                                                            Adults                                                Yes   Yes   No                                       No                                       Vh/Cr ("atrophic"), small intestine
  Rubio-Tapia et al. ([@B44])                                                                                                                            The USA (single-center)                                         Consecutive pts                                                                                   Adults                                                Yes   Yes   No                                       No                                       Vh/Cr\<3, duodenum
  Selby et al. ([@B45])                                                                                                                                  Australia (single-center)                                       Symptomatic and asymptomatic pts from a previous food-intolerance study                           Adults                                                Yes   Yes   No                                       No                                       Vh/Cr\<2, duodenum
  Souroujon et al. ([@B46])                                                                                                                              Israel (single-center)                                          Consecutive pts                                                                                   Adults and Children                                   Yes   Yes   Yes                                      Yes                                      Not reported ("atrophic"), small intestine
  Thornquist et al. ([@B50])                                                                                                                             Norway (single-center)                                          Consecutive pts by invitation                                                                     Adults                                                Yes   Yes   No                                       Yes/No[^c^](#TN3){ref-type="table-fn"}   Alexander III-IV, jejunum
  Tuire et al. ([@B51])                                                                                                                                  Finland (single-center)                                         Consecutive volunteers                                                                            Adults                                                Yes   Yes   No                                       Yes                                      Marsh 3, duodenum
  Valdimarsson et al. ([@B52])                                                                                                                           Sweden (single-center)                                          Consecutive pts with persistent villous atrophy and matched pts with mucosal recovery             Adults                                                (?)   Yes   No                                       No                                       Alexander III-IV, small intestine
  Walters et al. ([@B53])                                                                                                                                UK (single center)                                              Consecutive pts by invitation                                                                     Adults                                                Yes   No    No                                       Yes/No[^c^](#TN3){ref-type="table-fn"}   Not reported ("atrophic"), small intestine

Study population is considered representative to the average CeD population if the study avoided inappropriate exclusions.

The study observed a group of newly diagnosed CeD patients for the short-term and a group of followed-up patients for the long-term.

Not all patients were newly diagnosed.

*(?) indicates uncertainty. CeD, celiac disease; pts, patients; Vh/Cr, villous height/crypt depth ratio*.

Out of the 31 papers, eight retrieved data on different outcomes from the Swedish CeD registry; therefore, study populations partially overlap (Lebwohl et al., [@B27],[@B28], [@B29], [@B26],[@B30]; Emilsson et al., [@B13]; Kurien et al., [@B25]; Ludvigsson et al., [@B34]).

Highlights of the Last Five Years
---------------------------------

In this subchapter, we summarize the findings of the studies which investigated the prognostic role of follow-up histology and were published after January 2015 (Lebwohl et al., [@B27], [@B26]; Pekki et al., [@B41], [@B40]; Haere et al., [@B17]; Fang et al., [@B14]; Mahadev et al., [@B36]; Emilsson et al., [@B13]; Kurien et al., [@B25]; Ludvigsson et al., [@B34]). Eight studies were conducted in Scandinavia, one in the USA, and there was another multicenter study from Europe and North-America. Evidence from univariate analysis suggested a borderline association of PVA with persisting symptoms (OR = 1.656 with CI: 0.949--2.889; *p* = 0.076 favoring mucosal recovery) (Fang et al., [@B14]), which was not confirmed by co-variate-adjusted analysis of the baseline cohort of patients of a multicenter randomized trial on symptomatic CeD patients (Mahadev et al., [@B36]). Conclusions from three Scandinavian studies on symptom and well-being scores corroborated these findings (Pekki et al., [@B41], [@B40]; Haere et al., [@B17]). PVA might be associated with lower lumbar T-score measured at 1 year after diagnosis, although neither the risk of osteoporosis at 5 years after diagnosis nor that of fractures at 2 years after diagnosis was higher in this group (Pekki et al., [@B41], [@B40]). Decreased vitamin D and calcium levels might contribute to the impaired bone mineral density (Fang et al., [@B14]). Regarding other nutrients and minerals, zinc deficiency should be highlighted (39 vs. 14% in patients with PVA and MR, respectively; *p* = 0.0005). The effect of PVA did not manifest itself regarding erythropoiesis: three studies reported similar hemoglobin levels and rate of anemia in patients with PVA and MR (Pekki et al., [@B41]; Fang et al., [@B14]; Mahadev et al., [@B36]). Rate of malignant tumors and that of lymphomas were not significantly different in histology groups in two studies 5 and 8 years after diagnosis (Pekki et al., [@B41], [@B40]). Similar neutral associations were found on the rate of cardiovascular diseases (Lebwohl et al., [@B26]; Mahadev et al., [@B36]), serious infections including sepsis, streptococcal, pneumococcal, influenza, herpes zoster, and *Clostridium difficile* infections (Emilsson et al., [@B13]), and adverse pregnancy outcomes (Lebwohl et al., [@B30]). MR seemed to be a protective factor against respiratory and dermatological diseases (Pekki et al., [@B40]). In contrast, anxiety and depression co-occurred more frequently with MR (Ludvigsson et al., [@B34]) as did epilepsy (Kurien et al., [@B25]). With respect to overall mortality, a higher rate was reported with PVA on 8-years follow-up (14 vs. 9%) but the difference was not statistically significant (*p* = 0.259).

Narrative Review
----------------

In this subchapter, we summarize all available evidence published on the effect of MR and PVA on the outcomes of CeD.

### Symptoms, Symptom Scores and Quality of Life

In asymptomatic patients, PVA rates ranged from 2 to 62% (Walters et al., [@B53]; Bardella et al., [@B3]; Koskinen et al., [@B24]; Cornell et al., [@B10]). In symptomatic patients, PVA rate was 38% (Mahadev et al., [@B36]) ([Table 2](#T2){ref-type="table"}). Six studies reported symptoms as dichotomies (symptomatic vs. asymptomatic) (Thornquist et al., [@B50]; Selby et al., [@B45]; Kaukinen et al., [@B22]; Carroccio et al., [@B6]; Fang et al., [@B14]; Leonard et al., [@B32]). In univariate analysis, the percentage points of symptomatic patients with PVA and MR were 55 vs. 70% (*p* = NS) (Leonard et al., [@B32]), 69 vs. 57% (*p* = 0.076) (Fang et al., [@B14]), and 80 vs. 25% (*p* \< 0.0001) (Carroccio et al., [@B6]), respectively ([Table 3](#T3){ref-type="table"}). Only one study adjusted for reasonable co-variates where the adjusted OR was 3.2, 95% CI: 1.6--6.4 (*p* = 0.001), indicating that patients with PVA tended to be symptomatic more often (Carroccio et al., [@B6]). Regarding the individual symptoms, only one study adjusted for co-variates where none of the symptoms in focus, that is, diarrhea, bloating, abdominal pain, nausea, tiredness, constipation, heartburn and headache, was significantly associated with PVA (Mahadev et al., [@B36]) ([Table 3](#T3){ref-type="table"}).

###### 

Persistent villous atrophy in studies including only symptomatic or asymptomatic celiac patients.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                     **Symptoms assessed prospectively?**   **Symptoms assessed at the time of follow-up biopsy?**   **Only strict GFD?**   **Symptoms**                                **N^**0**^ of pts with persistent villous atrophy/total**\   **Timing of follow-up biopsy**\
                                                                                                                                                                                                   **(% of total)**                                             **(from CeD diagnosis)**
  ----------------------------- -------------------------------------- -------------------------------------------------------- ---------------------- ------------------------------------------- ------------------------------------------------------------ -------------------------------------------
  **ASYMPTOMATIC POPULATION**                                                                                                                                                                                                                                   

  Bardella et al. ([@B3])       No                                     Yes                                                      Yes                    Not specified                               71 cases/114 pts\                                            2 years (median) with 1--23 years (range)
                                                                                                                                                                                                   (62)                                                         

  Walters et al. ([@B53])       (?)                                    (?)                                                      Yes                    Not specified                               9 cases/17 pts\                                              2 years (min)
                                                                                                                                                                                                   (53)                                                         

  Koskinen et al. ([@B24])      Yes                                    Yes                                                      (?)                    Specified[^a^](#TN4){ref-type="table-fn"}   21 cases/71 pts (30)                                         1 years

                                Yes                                    Yes                                                      (?)                                                                2 cases/105 pts\                                             8 years (median) with 2--41 years (range)
                                                                                                                                                                                                   (2)                                                          

  Cornell et al. ([@B10])       Yes                                    Yes                                                      (?)                    Not specified                               9 cases/20 pts\                                              4 m-36 years (range)
                                                                                                                                                                                                   (45)                                                         

  **SYMPTOMATIC POPULATION**                                                                                                                                                                                                                                    

  Mahadev et al. ([@B36])       No                                     Yes                                                      Yes                    Specified[^b^](#TN5){ref-type="table-fn"}   511 cases/1,345 pts\                                         4 years (median) with 1 years (min)
                                                                                                                                                                                                   (38)                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Symptoms included abdominal complaints, malabsorption, and extraintestinal symptoms.

*Symptoms include bloating, tiredness, abdominal pain, diarrhea, nausea, constipation, heartburn, and headache. (?) indicates uncertainty. CeD, celiac disease; GFD, gluten-free diet; m, month; min, minimum; pts, patients*.

###### 

Presence of symptoms in celiac patients with persistent villous atrophy and mucosal recovery.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                              **Symptoms assessed prospectively?**   **Symptoms assessed at the time of follow-up biopsy?**   **Only strict GFD?**   **Symptoms**                                 **N^**0**^ of symptomatic pts/total with persistent villous**\   **N^**0**^ of symptomatic pts/total with mucosal recovery**\   **Statistics**\                                                                                                                                                                                                                      **Timing of follow-up biopsy**\
                                                                                                                                                                                                             **atrophy (% of total)**                                         **(% of total)**                                               **(atrophy vs. recovery)**                                                                                                                                                                                                           **(from CeD diagnosis)**
  -------------------------------------- -------------------------------------- -------------------------------------------------------- ---------------------- -------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------
  **SYMPTOMATIC vs. ASYMPTOMATIC PTS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Carroccio et al. ([@B6])               Yes                                    Yes                                                      Yes                    Specified[^a^](#TN6){ref-type="table-fn"}    36 cases/45 pts\                                                 6 cases/24 pts\                                                OR = 12\                                                                                                                                                                                                                             6.5 y and 6.1 y (means for groups) with 3.6 y and 4.6 y (SDs for groups)
                                                                                                                                                                                                             (80)                                                             (25)                                                           (CI: 3.7--38.9)\                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                             (*p* \< 0.0001, favors recovery);\                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                             **adjusted OR** **=** **3.2**\                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                             **(CI: 1.6--6.4)**\                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                             **(*p*** **=** **0.001, favors recovery)**[^***b***^](#TN7){ref-type="table-fn"}                                                                                                                                                     

  Fang et al. ([@B14])                   No                                     Yes                                                      Yes                    Specified[^c^](#TN8){ref-type="table-fn"}    53 cases/77 pts\                                                 116 cases/203 pts\                                             OR = 1.656\                                                                                                                                                                                                                          2 y (min)
                                                                                                                                                                                                             (69)                                                             (57)                                                           (CI: 0.949--2.889) (*p* = 0.076, favors recovery)                                                                                                                                                                                    

  Kaukinen et al. ([@B22])               Yes                                    No[^d^](#TN9){ref-type="table-fn"}                       Yes                    Not specified                                4 cases/13 pts\                                                  Not reported                                                   Not reported                                                                                                                                                                                                                         8 y and 10 y (medians for groups) with 3--30 y (range)
                                                                                                                                                                                                             (31)                                                                                                                                                                                                                                                                                                                                                                 

  Leonard et al. ([@B32])                No                                     Yes                                                      No                     Not specified                                11 cases/20 pts\                                                 58 cases/83 pts\                                               *p* = NS                                                                                                                                                                                                                             2.4 y (median) with 1--12 y (range) and 1.4--4 y (Q~1~-Q~3~)
                                                                                                                                                                                                             (55)                                                             (70)                                                                                                                                                                                                                                                                                                

  Selby et al. ([@B45])                  (?)                                    No[^e^](#TN10){ref-type="table-fn"}                      Yes                    Not specified                                5 cases/26 pts\                                                  3 cases/24 pts\                                                Not reported                                                                                                                                                                                                                         Not reported
                                                                                                                                                                                                             (19)                                                             (13)                                                                                                                                                                                                                                                                                                

  Thornquist et al. ([@B50])             Yes                                    No[^e^](#TN10){ref-type="table-fn"}                      Yes                    Specified[^f^](#TN11){ref-type="table-fn"}   1 case/4 pts\                                                    7 cases/9 pts\                                                 Not reported                                                                                                                                                                                                                         17 y (mean) with 15--18 y (range?)
                                                                                                                                                                                                             (25)                                                             (78)                                                                                                                                                                                                                                                                                                

  **SPECIFIC SYMPTOMs\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  (PRESENT vs. ABSENT)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Cammarota et al. ([@B5])               Yes                                    Yes                                                      No                     Diarrhea                                     10 cases/49 pts\                                                 2 cases/16 pts\                                                Not reported                                                                                                                                                                                                                         6--14 m (range)
                                                                                                                                                                                                             (20)                                                             (13)                                                                                                                                                                                                                                                                                                

                                                                                                                                                                Bloating                                     9 cases/49 pts\                                                  3 cases/16 pts\                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                             (18)                                                             (19)                                                                                                                                                                                                                                                                                                

                                                                                                                                                                Abdominal pain                               5 cases/49 pts\                                                  7 cases/16 pts\                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                             (10)                                                             (44)                                                                                                                                                                                                                                                                                                

  Carroccio et al. ([@B6])               Yes                                    Yes                                                      Yes                    Typical symptoms                             6 cases/45 pts\                                                  0 cases/24 pts\                                                *p* = 0.005 (favors recovery)                                                                                                                                                                                                        6.5 y and 6.1 y (means for groups) with 3.6 y and 4.6 y (SDs for groups)
                                                                                                                                                                                                             (13)                                                             (0)                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                GERD-like symptoms                           9 cases/45 pts\                                                  3 cases/24 (13)                                                *p* = 0.01 (favors recovery)                                                                                                                                                                                                         
                                                                                                                                                                                                             (20)                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                lower abdominal symptoms                     21 cases/45 pts\                                                 3 cases/21 pts\                                                *p* = 0.001 (favors recovery)                                                                                                                                                                                                        
                                                                                                                                                                                                             (47)                                                             (14)                                                                                                                                                                                                                                                                                                

  Ghazzawi et al. ([@B16])               No                                     Yes                                                      Yes                    Abdominal pain                               2 cases/5 pts\                                                   17 cases/34 pts\                                               Not reported                                                                                                                                                                                                                         2 y (mean) with 22 m (SD) and 4--120 m (range)
                                                                                                                                                                                                             (40)                                                             (50)                                                                                                                                                                                                                                                                                                

                                                                                                                                                                Diarrhea                                     2 cases/5 pts\                                                   5 cases/34 pts\                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                             (40)                                                             (15)                                                                                                                                                                                                                                                                                                

                                                                                                                                                                Constipation                                 0 cases/5 pts\                                                   5 cases/34 pts\                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                             (0)                                                              (15)                                                                                                                                                                                                                                                                                                

  Mahadev et al. ([@B36])                No                                     Yes                                                      Yes                    Bloating                                     431 cases/511 pts\                                               736 cases/834 pts\                                             *p* = 0.04 (favors atrophy), *p* = 0.001 (favors atrophy), *p* = 0.0009 (favors atrophy), and *p* = 0.04 (favors recovery) for bloating, abdominal pain, nausea, and heartburn, respectively; *p* = NS for the other comparisons;\   4 y (median) with 1 y (min)
                                                                                                                                                                                                             (84)                                                             (88)                                                           **adjusted** ***p*** **=** **NS for all comparisons**[^***g***^](#TN12){ref-type="table-fn"}                                                                                                                                         

                                                                                                                                                                Abdominal pain                               410 cases/511 pts\                                               724 cases/834 pts\                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                             (80)                                                             (87)                                                                                                                                                                                                                                                                                                

                                                                                                                                                                Tiredness                                    421 cases/511 pts\                                               708 cases/834\                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                             (82)                                                             (85)                                                                                                                                                                                                                                                                                                

                                                                                                                                                                Diarrhea                                     375 cases/511 pts\                                               643 cases/834pts\                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                             (73)                                                             (77)                                                                                                                                                                                                                                                                                                

                                                                                                                                                                Nausea                                       239 cases/511 pts\                                               451 cases/834 pts\                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                             (47)                                                             (54)                                                                                                                                                                                                                                                                                                

                                                                                                                                                                Constipation                                 263 cases/511 pts\                                               421 cases/834 pts\                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                             (51)                                                             (50)                                                                                                                                                                                                                                                                                                

                                                                                                                                                                Heartburn                                    140 cases/511 pts\                                               186 cases/834 pts\                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                             (27)                                                             (22)                                                                                                                                                                                                                                                                                                

                                                                                                                                                                Headache                                     112 cases/511 pts\                                               208 cases/834 pts\                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                             (22)                                                             (25)                                                                                                                                                                                                                                                                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Multivariate analyses are highlighted with bold.

Symptoms included typical (chronic diarrhea, weight loss, anemia), GERD-like, and lower abdominal symptoms (abdominal pain, constipation).

Analysis was adjusted for age, gender, duration of GFD, diagnostic histological severity.

Symptoms included abdominal pain, bloating, nausea, fatigue, diarrhea, bloody stool, steatorrhea, and weight loss.

Symptoms were assessed 4--5 years after the follow-up biopsy.

Symptoms were evaluated after follow-up biopsy (interval undetermined).

Symptoms included gastrointestinal and malabsorptive symptoms, such as diarrhea, borborygmi, abdominal pain, fatty stool, and anemia.

*The analysis was adjusted for age, gender, body mass index, duration of GFD, medications, and laboratory tests. (?) indicates uncertainty. CeD, celiac disease; CI, confidence interval; GERD, gastroesophageal reflux disease; GFD, gluten-free diet; m, month; min, minimum; OR, odds ratio; pts, patients; NS, non-significant; SD, standard deviations; Q~1~-Q~3~, 25 and 75% quartiles; y, year*.

Five studies (Kaukinen et al., [@B22]; Tuire et al., [@B51]; Pekki et al., [@B41], [@B40]; Haere et al., [@B17]) reported gastrointestinal symptom scores measured with the Gastrointestinal Symptom Rating Scale (GSRS) or its irritable bowel syndrome-adapted version (GSRS-IBS). Four of which performed statistical analysis and reported no association between histology and the scores consistently (Kaukinen et al., [@B22]; Pekki et al., [@B41], [@B40]; Haere et al., [@B17]) ([Table 4](#T4){ref-type="table"}). Results were similar in quality of life measured with the Psychological General Well-Being Index (PGWB) and/or the 36-Item Short Form Health Survey (SF-36) (Kaukinen et al., [@B22]; Tuire et al., [@B51]; Pekki et al., [@B41], [@B40]) ([Table 4](#T4){ref-type="table"}).

###### 

Symptom scores and quality of life indices in celiac patients with persistent villous atrophy and mucosal recovery.

  **Study**                             **Symptoms assessed prospectively?**   **Symptoms assessed at the time of follow-up biopsy?**   **Only strict GFD?**   **Tool**                                    **Persistent villous atrophy**         **Mucosal recovery**                **Statistics (atrophy vs. recovery)**   **Timing of follow-up biopsy (from CeD diagnosis)**                  
  ------------------------------------- -------------------------------------- -------------------------------------------------------- ---------------------- ------------------------------------------- -------------------------------------- ----------------------------------- --------------------------------------- ----------------------------------------------------- -------------- --------------------------------------------------------
  **GASTROINTESTINAL SYMPTOM SCORES**                                                                                                                                                                                                                                                                                                                                                              
  Pekki et al. ([@B40])                 Yes                                    No[^a^](#TN13){ref-type="table-fn"}                      No                     GSRS                                        200                                    Not reported                        276                                     Not reported                                          *p* = NS       1 y
  Kaukinen et al. ([@B22])              Yes                                    Yes                                                      Yes                    GSRS                                        13                                     mean: 2.0 (CI: 1.4--2.6)            18                                      mean: 2.0 (CI: 1.7--2.3)                              *p* = NS       8 y and 10 y (medians for groups) with 3--30 y (range)
  Pekki et al. ([@B41])                 Yes                                    Yes                                                      No                     GSRS                                        85                                     Median: 1.5 (Q~1~-Q~3~: 1.3--1.8)   178                                     Median: 1.5 (Q~1~-Q~3~: 1.3-2.0)                      *p* = 0.321    1 y
                                                                               No[^a^](#TN13){ref-type="table-fn"}                      No                     GSRS                                        ∑44[^b^](#TN14){ref-type="table-fn"}   Median: 1.6 (Q~1~-Q~3~: 1.0--4.0)   ∑44[^b^](#TN14){ref-type="table-fn"}    Median: 1.9 (Q~1~-Q~3~: 1.0--3.0)                     *p* = 0.132    5 y (median)
  Tuire et al. ([@B51])                 Yes                                    Yes                                                      Yes                    GSRS[^c^](#TN15){ref-type="table-fn"}       7                                      Mean: 1.73 (CI: 1.39-2.07)          170                                     Not reported                                          Not reported   2--41 y (range)
  Haere et al. ([@B17])                 Yes                                    Yes                                                      No                     GSRS-IBS[^d^](#TN16){ref-type="table-fn"}   7                                      Mean: 25.1 (*SD* 9.9)               116                                     Mean: 26.4 (*SD*: 9.9)                                *p* = NS       9.3 y (mean) with 5 y (*SD*) and 2 y (min)
  **QUALITY OF LIFE SCORES**                                                                                                                                                                                                                                                                                                                                                                       
  Pekki et al. ([@B40])                 Yes                                    No[^a^](#TN13){ref-type="table-fn"}                      No                     PGWB                                        200                                    Not reported                        276                                     Not reported                                          *p* = NS       1 y
                                                                                                                                                               SF-36                                                                                                                                                                                                                *p* = NS       
  Kaukinen et al. ([@B22])              Yes                                    Yes                                                      Yes                    PGWB                                        13                                     Mean: 101 (CI: 94-108)              18                                      Mean: 101 (CI: 92-110)                                *p* = NS       8 y and 10 y (medians for groups) with 3--30 y (range)
  Pekki et al. ([@B41])                 Yes                                    Yes                                                      No                     PGWB                                        85                                     Median: 112 (Q~1~-Q~3~: 102--118)   178                                     Median: 111 (Q~1~-Q~3~: 100--117)                     *p* = 0.699    1 y
                                                                               No[^a^](#TN13){ref-type="table-fn"}                      No                     PGWB                                        ∑44[^b^](#TN14){ref-type="table-fn"}   median: 109 (Q~1~-Q~3~: 52--124)    ∑44[^b^](#TN14){ref-type="table-fn"}    Median: 108 (Q~1~-Q~3~: 62--121)                      *p* = 0.416    5 y (median)
  Tuire et al. ([@B51])                 Yes                                    Yes                                                      Yes                    PGWB[^b^](#TN14){ref-type="table-fn"}       7                                      Mean: 112.7 (CI: 110.6--114.8)      170                                     Not reported                                          Not reported   2--41 y (range)

Scores were assessed years after the follow-up biopsy.

The number of patients were not reported for atrophic and recovery groups separately.

Subdimensions of GSRS were reported within the original article in detail.

*A 3-day modified version of the original tool was used. CeD, celiac disease; CI, confidence interval; GFD, gluten-free diet; GSRS, Gastrointestinal Symptom Rating Scale; GSRS-IBS: Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome; min, minimum; NS, non-significant; PGWB, Psychological General Well-Being; pts, patients; SF-36, Short Form Health Survey-36; Q~1~-Q~3~, 25% and 75% quartiles; SD: standard deviation*.

### Metabolic Bone Disease and Bone Fractures

Four studies assessed bone mineral density in univariate analysis (Valdimarsson et al., [@B52]; Walters et al., [@B53]; Kaukinen et al., [@B22]; Pekki et al., [@B41]) ([Table 5](#T5){ref-type="table"}). Patients with PVA tended to have lower forearm, femoral and trochanter Z-scores (Valdimarsson et al., [@B52]); and lower femoral T-score with similar femoral Z- and lumbar T- and Z-scores than those with MR (Pekki et al., [@B41]). One study showed a reduced bone mineral density with PVA (OR = 24.5, *p* \< 0.0275 favoring MR) (Walters et al., [@B53]). Two studies investigated the risk of osteoporosis in the long-term and reported conflicting results: a case-control study reported an increased frequency of osteoporosis with PVA (Kaukinen et al., [@B22]) but a cohort study failed to confirm (Pekki et al., [@B41]).

###### 

Bone mineral density in celiac patients with persistent villous atrophy and mucosal recovery.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                         **Parameter of interest assessed prospectively?**   **Parameter of interest assessed at the time of follow-up biopsy?**   **Only strict GFD?**   **Bone mineral density**                          **Persistent villous atrophy**                                        **Mucosal recovery**                                        **Statistics (atrophy vs. recovery)**   **Timing of follow-up biopsy**\                                              
                                                                                                                                                                                                                                                                                                                                                                                                                 **(from CeD diagnosis)**                                                     
  --------------------------------- --------------------------------------------------- --------------------------------------------------------------------- ---------------------- ------------------------------------------------- --------------------------------------------------------------------- ----------------------------------------------------------- --------------------------------------- -------------------------------------------------------- ------------------- -------------------------------------------------------
  **T- AND Z-SCORES**                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Pekki et al. ([@B41])             Yes                                                 Yes                                                                   No                     Lumbar (T-score)                                  Median: −1.1\                                                         ∑152[^a^](#TN17){ref-type="table-fn"}                       Median: −0.7\                           ∑152[^a^](#TN17){ref-type="table-fn"}                    *p* = 0.117         1 y
                                                                                                                                                                                                                                       (Q~1~-Q~3~: −2.2 to−0.2)                                                                                                          (Q~1~-Q~3~: −1.7 to 0.4)                                                                                             

                                                                                                                                                                                     Femoral neck (T-score)                            Median: −1.1\                                                         85 pts                                                      Median: −0.6\                           178 pts                                                  *p* = 0.024\        
                                                                                                                                                                                                                                       (Q~1~-Q~3~: −1.9 to−0.5)                                                                                                          (Q~1~-Q~3~: −1.5 to 0.0)                                                                         (favors recovery)   

                                                                                                                                                                                     Lumbar (Z-score)                                  Median: −0.5\                                                         ∑159[^a^](#TN17){ref-type="table-fn"}                       Median: 0.1\                            ∑159[^a^](#TN17){ref-type="table-fn"}                    *p* = 0.376         
                                                                                                                                                                                                                                       (Q~1~-Q~3~: −1.3 to −0.1)                                                                                                         (Q~1~-Q~3~: −1.1 to 0.9)                                                                                             

                                                                                                                                                                                     Femoral neck (Z-score)                            Median: −0.5\                                                         ∑140[^a^](#TN17){ref-type="table-fn"}                       Median: −0.3\                           ∑140[^a^](#TN17){ref-type="table-fn"}                    *p* = 0.323         
                                                                                                                                                                                                                                       (Q~1~-Q~3~: −0.7 to −0.1)                                                                                                         (Q~1~-Q~3~: −0.6 to 0.3)                                                                                             

  Valdimarsson et al. ([@B52])      Yes                                                 (?)                                                                   No                     Forearm (Z-score)                                 Not reported                                                          13 pts                                                      Not reported                            17 pts                                                   *P* \< 0.01\        8 y and 9 y (medians for groups) with 4--14 y (range)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                          (favors recovery)   

                                                                                                                                                                                     Femoral neck (Z-score)                                                                                                                                                                                                                                                               *p* \< 0.01\        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                          (favors recovery)   

                                                                                                                                                                                     Femoral trochanter (Z-score)                                                                                                                                                                                                                                                         *p* \< 0.05\        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                          (favors recovery)   

                                                                                                                                                                                                                                       **Affected pts/total with persistent villous atrophy (% of total)**   **Affected pts/total with mucosal recovery (% of total)**                                                                                                                        

  **OSTEOPOROSIS AND OSTEOPENIA**                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Kaukinen et al. ([@B22])          Yes                                                 Yes                                                                   Yes                    Osteoporosis (T-score ≤−2.5 *SD*)                 7 cases/12 pts\                                                       4 cases/18 pts\                                             *p* = 0.04                              8 y and 10 y (medians for groups) with 3--30 y (range)                       
                                                                                                                                                                                                                                       (58)                                                                  (22)                                                                                                                                                                             

                                                                                                                                                                                     Osteopenia (T-score between −1.0 and −2.4 *SD*)   4 cases/12 pts\                                                       8 cases/18 pts\                                             *p* = NS                                                                                                             
                                                                                                                                                                                                                                       (33)                                                                  (44)                                                                                                                                                                             

  Pekki et al. ([@B41])             Yes                                                 No[^b^](#TN18){ref-type="table-fn"}                                   No                     Osteoporosis (T- and Z-scores)                    8 cases/71 pts\                                                       16 cases/134 pts\                                           *p* = 0.850                             5 y (median)                                                                 
                                                                                                                                                                                                                                       (14)                                                                  (13)                                                                                                                                                                             

  Walters et al. ([@B53])           Yes                                                 No[^b^](#TN18){ref-type="table-fn"}                                   Yes                    Osteopenia (Z-score)                              7 cases/9 pts\                                                        1 case/8 pts\                                               *p* \< 0.0275\                          2 y (min)                                                                    
                                                                                                                                                                                                                                       (78)                                                                  (13)                                                        (favors recovery)                                                                                                    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All measurements were performed with dual-energy X-ray absorptiometry except in forearm bone mineral density in the study of Valdimarsson et al. ([@B52]) which used single-photon absorptiometry.

The number of patients were not reported for atrophic and recovery groups separately.

*Parameter was assessed years after follow-up biopsy. (?) indicates uncertainty. GFD, gluten-free diet; m, month; min, minimum; NS, non-significant; pts, patients Q~1~-Q~3~, 25% and 75% quartiles; SD, standard deviation; y, year*.

Three studies (Valdimarsson et al., [@B52]; Lebwohl et al., [@B29]; Pekki et al., [@B40]) reported no association between fractures and follow-up histology, except in the frequency of hip fractures being seemingly increased after a 5-years follow-up with PVA (adjusted HR = 2.18, CI: 1.17--4.05) (Lebwohl et al., [@B29]) ([Table 6](#T6){ref-type="table"}).

###### 

Fractures in celiac patients with persistent villous atrophy and mucosal recovery.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                      **Events assessed prospectively?**   **Only strict GFD?**   **Type of fracture**                                            **Persistent villous atrophy**   **Mucosal recovery**            **Statistics (atrophy vs. recovery)**                     **Timing of follow-up biopsy**\                         **Follow-up period**
                                                                                                                                                                                                                                                                                        **(from CeD diagnosis)**                                
  ------------------------------ ------------------------------------ ---------------------- --------------------------------------------------------------- -------------------------------- ------------------------------- --------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------------------
  Valdimarsson et al. ([@B52])   Yes                                  No                     Any fracture                                                    9 fractures in 6 cases/13 pts    5 fractures in 5 cases/17 pts   *p* = NS for the number of patients with fractures        8 y and 9 y (medians for groups) with 4--14 y (range)   Not reported

  Pekki et al. ([@B40])          Yes                                  No                     Any fracture                                                    53 cases/200 pts                 80 cases/276 pts                *p* = 0.859                                               1 y                                                     Years (?)

  Lebwohl et al. ([@B29])        No                                   (?)                    Any fracture[^a^](#TN19){ref-type="table-fn"}                   492 cases/34409 PYO              483 cases/36418 PYO             **HR** **=** **0.93\                                      6 m−5 y (range)                                         8.6 y (median) with 6.9--15.7 y (Q~1~-Q~3~) from follow-up biopsy
                                                                                                                                                                                                                              (CI: 0.82--1.06)**[^**b**^](#TN20){ref-type="table-fn"}                                                           

                                                                                             Likely osteoporotic fracture[^a^](#TN19){ref-type="table-fn"}   124 cases/20617 PYO              96 cases/11916 PYO              **HR** **=** **1.11\                                                                                              
                                                                                                                                                                                                                              (CI: 0.84-1.46)**[^**b**^](#TN20){ref-type="table-fn"}                                                            

                                                                                             Hip fracture[^a^](#TN19){ref-type="table-fn"}                   26 cases/37925 PYO               63 cases/39851 PYO              **HR** **=** **1.67\                                                                                              
                                                                                                                                                                                                                              (CI: 1.05--2.66)**^**b**^\                                                                                        
                                                                                                                                                                                                                              **(favors recovery)**                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Multivariate analyses are highlighted with bold.

Detailed data are available in the original article.

*The analysis was adjusted for age, gender, duration of celiac disease, calendar period, and educational attainment. (?) indicates uncertainty. CI, confidence interval; GFD, gluten-free diet; HR, hazard ratio (reference group: mucosal recovery); NS, non-significant; PYO, person-years observation; Q~1~-Q~3~: 25 and 75% quartiles*.

### Micro- and Macronutrients

[Table 7](#T7){ref-type="table"} summarizes the laboratory findings.

###### 

Vitamins, minerals, and homocysteine in celiac patients with persistent villous atrophy and mucosal recovery.

  **Study**                               **Parameter of interest assessed prospectively?**   **Parameter of interest assessed at the time of follow-up biopsy?**   **Only strict GFD?**   **Laboratory study**                                                 **Persistent villous atrophy**          **Mucosal recovery**   **Statistics (atrophy vs. recovery)**           **Timing of follow-up biopsy (from CeD diagnosis)**                                                                                               
  --------------------------------------- --------------------------------------------------- --------------------------------------------------------------------- ---------------------- -------------------------------------------------------------------- --------------------------------------- ---------------------- ----------------------------------------------- ----------------------------------------------------- --------- ----------------------------------------------- --------------------------------- -------------------------------------------------------
  **VITAMIN B**~**2**~ **(RIBOFLAVIN)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Dickey et al. ([@B12])                  Yes                                                 Yes                                                                   Yes                    EGRAC                                                                24                                                             Mean: 1.38 (*SD*: 0.19)                         41                                                              Mean: 1.28 (SD: 0.13)                           Not reported                      1 y (min)
  **VITAMIN B**~**6**~ **(PYRIDOXINE)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Dickey et al. ([@B12])                  Yes                                                 Yes                                                                   Yes                    Plasma pyridoxal phosphate (nmol/l, vitamin)                         24                                                             Mean: 69.9 (*SD*: 24.0)                         41                                                              Mean: 91.0 (*SD*: 43.3)                         Not reported                      1 y (min)
  **VITAMIN B**~**9**~ **(FOLIC ACID)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Dickey et al. ([@B12])                  Yes                                                 Yes                                                                   Yes                    Erythrocyte folic acid (nmol/l)                                      24                                                             Mean: 900 (*SD*: 574)                           41                                                              Mean: 1048 (*SD*: 791)                          Not reported                      1 y (min)
  Dickey et al. ([@B12])                  Yes                                                 Yes                                                                   Yes                    Serum folic acid (nmol/l)                                            24                                                             Mean: 23.5 (SD: 22.8)                           41                                                              Mean: 25.7 (SD: 31.5)                           Not reported                      1 y (min)
  Kemppainen et al. ([@B23])              No                                                  Yes                                                                   (?)                    Erythrocyte folic acid *(cut-off: not reported)*                     37                                      3 (8)                                                                  3                                                     0 (0)                                                     Not reported                      1 y
  Pekki et al. ([@B41])                   Yes                                                 Yes                                                                   No                     Erythrocyte folic acid (nmol/l)                                      ∑142[^a^](#TN21){ref-type="table-fn"}                          Median: 548 (Q~1~-Q~3~: 424--676)               ∑142[^a^](#TN21){ref-type="table-fn"}                           Median: 508 (Q~1~-Q~3~: 383--650)               *p* = 0.547                       1 y
  Thornquist et al. ([@B50])              Yes                                                 No[^b^](#TN22){ref-type="table-fn"}                                   No                     Serum folic acid                                                     4                                                              Not reported^d^                                 9                                                               Not reported^d^                                 Not reported                      17 y (mean) with 15--18 y (range ?)
  Tuire et al. ([@B51])                   Yes                                                 Yes                                                                   Yes                    Erythrocyte folic acid (nmol/l)                                      7                                                              Median: 486 (range: 243--1,849)                 170                                                             Not reported                                    Not reported                      2--41 y (range)
  **VITAMIN B**~**12**~ **(COBALAMIN)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Dickey et al. ([@B12])                  Yes                                                 Yes                                                                   Yes                    Serum vitamin B~12~ (pmol/l)                                         24                                                             Mean: 242.5 (SD: 105.8)                         41                                                              Mean: 276.6 (SD: 137.1)                         Not reported                      1 y (min)
  Fang et al. ([@B14])                    No                                                  No[^c^](#TN23){ref-type="table-fn"}                                   Yes                    Serum vitamin B~12~ *(cut-off: 180 ng/l)*                            60                                      2 (3)                                                                  175                                                   3 (2)                                                     *p* = 0.6023                      2 y (min)
  Kemppainen et al. ([@B23])              No                                                  Yes                                                                   (?)                    Serum vitamin B~12~ *(cut-off: not reported)*                        37                                      1 (3)                                                                  3                                                     0 (0)                                                     Not reported                      1 y
  Pekki et al. ([@B41])                   Yes                                                 Yes                                                                   No                     Serum vitamin B~12~ (pmol/l)                                         85                                                             Median: 383 (Q~1~-Q~3~: 286--464)               178                                                             Median: 341 (Q~1~-Q~3~: 269-428)                *p* = 0.153                       1 y
  Thornquist et al. ([@B50])              Yes                                                 No[^b^](#TN22){ref-type="table-fn"}                                   No                     Serum vitamin B~12~                                                  4                                                              Not reported[^d^](#TN24){ref-type="table-fn"}   9                                                               Not reported[^d^](#TN24){ref-type="table-fn"}   Not reported                      17 y (mean) with 15--18 y (range ?)
  **VITAMIN A (RETINOL)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Kemppainen et al. ([@B23])              No                                                  Yes                                                                   (?)                    Serum vitamin A *(cut-off: not reported)*                            37                                      5 (14)                                                                 3                                                     0 (0)                                                     Not reported                      1 y
  **VITAMIN D (CHOLECALCIFEROL)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Fang et al. ([@B14])                    No                                                  No[^c^](#TN23){ref-type="table-fn"}                                   Yes                    Serum total 25-hydroxy vitamin D~2~ and D~3~ *(cut-off: 25 ng/ml)*   55                                      17 (31)                                                                174                                                   14 (8)                                                    *p* = 0.0001 (favors recovery)    2 y (min)
  Valdimarsson et al. ([@B52])            Yes                                                 (?)                                                                   No                     Serum 25-hydroxy vitamin D                                           13                                                             Median: 52 (range: 18--91)                      17                                                              Median: 80 (range: 37-95)                       *p* \< 0.05 (favors recovery)     8 y and 9 y (medians for groups) with 4--14 y (range)
  **IRON AND FERRITIN**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Fang et al. ([@B14])                    No                                                  No[^c^](#TN23){ref-type="table-fn"}                                   Yes                    Serum ferritin *(cut-off: males: 24 mcg/l, females: 11 mcg/l)*       69                                      7 (10)                                                                 165                                                   21 (13)                                                   *p* = 0.6636                      2 y (min)
  Kemppainen et al. ([@B23])              No                                                  Yes                                                                   (?)                    Serum total iron *(cut-off: not reported)*                           37                                      15 (41)                                                                3                                                     0 (0)                                                     Not reported                      1 y
  Kemppainen et al. ([@B23])              No                                                  Yes                                                                   (?)                    Serum ferritin *(cut-off: not reported)*                             37                                      5 (14)                                                                 3                                                     0 (0)                                                     Not reported                      1 y
  Pekki et al. ([@B41])                   Yes                                                 Yes                                                                   No                     Serum total iron (μmol/l)                                            ∑144[^a^](#TN21){ref-type="table-fn"}                          Median: 19.6 (Q~1~-Q~3~: 13.4--24.4)            ∑144[^a^](#TN21){ref-type="table-fn"}                           Median: 17.6 (Q~1~-Q~3~: 14.0-21.5)             *p* = 0.245                       1 y
  Souroujon et al. ([@B46])               Yes                                                 Yes                                                                   (?)                    Serum ferritin                                                       2                                                              Mean: 16.2 (SD: 1.38)                           34                                                              Mean: 25.7 (SD: 1.82)                           Not reported                      1 y
  **CALCIUM**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Fang et al. ([@B14])                    No                                                  No[^c^](#TN23){ref-type="table-fn"}                                   Yes                    Serum total calcium *(cut-off: 8.9 mg/dl)*                           65                                      13 (20)                                                                164                                                   4 (2)                                                     *p* \< 0.0001 (favors recovery)   2 y (min)
  Pekki et al. ([@B41])                   Yes                                                 Yes                                                                   No                     Serum ionized calcium (mmol/l)                                       ∑95[^a^](#TN21){ref-type="table-fn"}                           Median: 1.25 (Q~1~-Q~3~: 1.21-1.28)             ∑95[^a^](#TN21){ref-type="table-fn"}                            Median: 1.24 (Q~1~-Q~3~: 1.21-1.27)             *p* = 0.708                       1 y
  Valdimarsson et al. ([@B52])            Yes                                                 (?)                                                                   No                     Serum ionized calcium (mmol/l)                                       13                                                             Median: 1.24 (range: 1.16-1.31)                 17                                                              Median: 1.24 (range: 1.19-1.34)                 *p* = NS                          8 y and 9 y (medians for groups) with 4--14 y (range)
  **ZINC**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Fang et al. ([@B14])                    No                                                  No[^c^](#TN23){ref-type="table-fn"}                                   Yes                    serum zinc *(cut-off: 0.66 mcg/ml)*                                  46                                      18 (39)                                                                145                                                   20 (14)                                                   *p* = 0.0005 (favors recovery)    2 y (min)
  Kemppainen et al. ([@B23])              No                                                  Yes                                                                   (?)                    serum zinc *(cut-off: not reported)*                                 37                                      10 (27)                                                                3                                                     0 (0)                                                     Not reported                      1 y
  **COPPER**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Fang et al. ([@B14])                    No                                                  No[^c^](#TN23){ref-type="table-fn"}                                   Yes                    Serum copper (0.75 mcg/ml)                                           51                                      0 (0)                                                                  149                                                   4 (3)                                                     *p* = 0.5740                      2 y (min)
  **HOMOCYSTEINE**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Dickey et al. ([@B12])                  Yes                                                 Yes                                                                   Yes                    Plasma homocysteine (μmol/l)                                         24                                                             Mean: 11.4 (SD: 5.5)                            41                                                              Mean: 10.4 (SD: 2.6)                            Not reported                      1 y (min)

Only the total N^0^ of pts was given.

Parameter was measured years after the follow-up biopsy.

Parameter was measured within 1 month of follow-up biopsy.

*Values were within the normal range for all patients and not reported for recovery and atrophic groups separately. (?) indicates uncertainty. CeD, celiac disease; EGRAC, erythrocyte glutathione reductase activation coefficient; GFD, gluten-free diet; m, month; min, minimum; NS, non-significant; Q~1~-Q~3~, 25% and 75% quartiles; SD, standard deviation; y, year*.

The association of water-soluble vitamins and follow-up histology is understudied. We found the numerical values of vitamins B~2~ and B~6~ levels or their laboratory indicators in patients with MR and PVA but the studies did not perform statistical comparison (Dickey et al., [@B12]). Regarding vitamins B~12~ and B~9~ (folic acid) levels, studies found no difference between groups by histology (Pekki et al., [@B41]; Fang et al., [@B14]). No reports are available on other water-soluble vitamins.

Reports on fat-soluble vitamins are scarce. Only numerical data are available on vitamin A without statistical comparison made by the authors (Valdimarsson et al., [@B52]). Patients with PVA tended to have lower 25-hydroxyvitamin D level \[and total calcium (Fang et al., [@B14])\], though serum parathyroid hormone (Valdimarsson et al., [@B52]; Pekki et al., [@B41]), ionized calcium (Valdimarsson et al., [@B52]; Pekki et al., [@B41]) and alkaline phosphatase (Valdimarsson et al., [@B52]) seemed similar in patients with MR and PVA.

Zinc but not copper deficiency may be associated with PVA (39 vs. 14% for zinc deficiency with PVA and MR, respectively, *p* = 0.0005) (Fang et al., [@B14]).

### Anemia

Nine studies reported on hemoglobin, four studies in dichotomies (aaemic vs. non-anemic) and five as continuous data (Thornquist et al., [@B50]; Kemppainen et al., [@B23]; Ciacci et al., [@B8]; Cammarota et al., [@B5]; Kaukinen et al., [@B22]; Tuire et al., [@B51]; Pekki et al., [@B41]; Fang et al., [@B14]; Mahadev et al., [@B36]), of which four reported statistical comparisons (Kaukinen et al., [@B22]; Pekki et al., [@B41]; Fang et al., [@B14]; Mahadev et al., [@B36]) ([Table 8](#T8){ref-type="table"}). Hemoglobin levels proved to be not statistically different in two studies (Kaukinen et al., [@B22]; Pekki et al., [@B41]). Another two studies examined the frequency of anemia (Fang et al., [@B14]; Mahadev et al., [@B36]), of which one found it more frequent with PVA (22 vs. 18%, *p* = 0.04) (Mahadev et al., [@B36]). However, the association was not confirmed after adjusting for co-variates (*p* = 0.236).

###### 

Anemia and hemoglobin levels in celiac patients with persistent villous atrophy and mucosal recovery.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                    **Parameter of interest assessed prospectively?**   **Parameter of interest assessed at the time of follow-up biopsy?**   **Only strict GFD?**   **Laboratory study**                                      **Persistent villous atrophy**   **Mucosal recovery**   **Statistics (atrophy vs. recovery)**           **Timing of follow-up biopsy (from CeD diagnosis)**                                                                                                                             
  ---------------------------- --------------------------------------------------- --------------------------------------------------------------------- ---------------------- --------------------------------------------------------- -------------------------------- ---------------------- ----------------------------------------------- ----------------------------------------------------- ---------- ----------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------
  Cammarota et al. ([@B5])     Yes                                                 Yes                                                                   No                     Iron-deficiency anemia *(Hb cut-off: not reported)*       49                               16 (33)                                                                16                                                    4 (25)                                                     Not reported                                                   6--14 m (range)

  Ciacci et al. ([@B8])        No                                                  Yes                                                                   No                     Hb (g/l)                                                  93                                                      Mean: 133                                       297                                                              Not reported[^a^](#TN25){ref-type="table-fn"}   Not reported                                                   7.78 y (mean)

  Fang et al. ([@B14])         No                                                  No[^b^](#TN26){ref-type="table-fn"}                                   Yes                    anemia (*Hb cut-off: males: 135 g/l, females: 120 g/l*)   97                               14 (14)                                                                249                                                   32 (13)                                                    *p* = 0.7255                                                   2 y (min)

  Kaukinen et al. ([@B22])     Yes                                                 Yes                                                                   Yes                    Hb (g/l)                                                  13                                                      mean: 121 (CI: 114--128)                        18                                                               Mean: 13.2 (CI: 12.6--13.8)                     *p* = NS                                                       8 y and 10 y (medians for groups) with 3--30 y (range)

  Kemppainen et al. ([@B23])   No                                                  Yes                                                                   (?)                    anemia *(Hb cut-off: not reported)*                       37                               7 (19)                                                                 3                                                     1 (33)                                                     Not reported                                                   1 y

  Mahadev et al. ([@B36])      No                                                  Yes                                                                   Yes                    anemia *(Hb cut-off: not reported)*                       511                              114 (22)                                                               834                                                   148 (18)                                                   unadjusted\                                                    4 y (median) with 1 y (min)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   *p* = 0.04, **adjusted**\                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ***p*** **=** **0.236**[^**c**^](#TN27){ref-type="table-fn"}   

  Pekki et al. ([@B41])        Yes                                                 Yes                                                                   No                     Hb (g/l)                                                  ∑153^f^                                                 Median: 145 (Q~1~-Q~3~: 134--150)               ∑153^f^                                                          Median: 147 (Q~1~-Q~3~: 147-151)                *p* = 0.342                                                    1 y

  Thornquist et al. ([@B50])   Yes                                                 No[^d^](#TN28){ref-type="table-fn"}                                   No                     Hb                                                        4                                                       Not reported[^e^](#TN29){ref-type="table-fn"}   9                                                                Not reported[^e^](#TN29){ref-type="table-fn"}   Not reported                                                   17 y (mean) with 15--18 y (range ?)

  Tuire et al. ([@B51])        Yes                                                 Yes                                                                   Yes                    Hb (g/l)                                                  7                                                       Median: 140 (range: 128--161)                   170                                                              Not reported[^a^](#TN25){ref-type="table-fn"}   Not reported                                                   2--41 y (range)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Multivariate analyses are highlighted with bold.

Values were given by Marsh 0 and 1--2 separately.

Parameter was assessed within 1-month of follow-up biopsy.

The analysis was adjusted for age, gender, body mass index, duration of GFD, medications, laboratory tests, and symptoms.

Parameter was measured years after the follow-up biopsy.

*Values by recovery and atrophy were not reported separately. (?) indicates uncertainty. CeD, celiac disease; CI: confidence interval; GFD, gluten-free diet; Hb, hemoglobin; m, month; min, minimum; NS, non-significant; Q~1~-Q~3~, 25% and 75% quartiles; SD, standard deviation; y, year*.

### Body Mass Index

Of the six studies reporting body mass index, three provided statistical evidence on having no significant difference between groups while the other three reported numerical values without analysis (Valdimarsson et al., [@B52]; Kaukinen et al., [@B22]; Dickey et al., [@B12]; Tuire et al., [@B51]; Pekki et al., [@B41]; Cornell et al., [@B10]) ([Table 9](#T9){ref-type="table"}).

###### 

Body mass index in celiac patients with persistent villous atrophy and mucosal recovery.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                      **Parameter of interest assessed prospectively?**   **Parameter of interest assessed at the time of follow-up biopsy?**   **Only strict GFD?**   **Persistent villous atrophy**   **Mucosal recovery**      **Statistics (atrophy vs. recovery)**   **Time between the diagnosis of CeD and follow-up biopsy**                  
  ------------------------------ --------------------------------------------------- --------------------------------------------------------------------- ---------------------- -------------------------------- ------------------------- --------------------------------------- ------------------------------------------------------------ -------------- --------------------------------------------------------
  Cornell et al. ([@B10])        Yes                                                 Yes                                                                   (?)                    9                                Mean: 22.72\              11                                      Mean: 24.26\                                                 Not reported   4 m-36 y (range)
                                                                                                                                                                                                                   (SD: 3.10)                                                        (SD: 3.70)                                                                  

  Dickey et al. ([@B12])         Yes                                                 Yes                                                                   Yes                    24                               Mean: 25.7\               41                                      Mean: 24.9\                                                  Not reported   1 y (min)
                                                                                                                                                                                                                   (SD: 4.7)                                                         (SD: 3.9)                                                                   

  Kaukinen et al. ([@B22])       Yes                                                 Yes                                                                   Yes                    13                               Mean: 23\                 18                                      Mean: 26\                                                    *p* = NS       8 y and 10 y (medians for groups) with 3--30 y (range)
                                                                                                                                                                                                                   (range: 18--29)                                                   (range: 19--35)                                                             

  Pekki et al. ([@B41])          Yes                                                 Yes                                                                   No                     ∑136^a^                          Median: 23.9\             ∑136^a^                                 Median: 24.3\                                                *p* = 0.823    1 y
                                                                                                                                                                                                                   (Q~1~-Q~3~: 22.0--27.3)                                           (Q~1~-Q~3~: 22.1--27.1)                                                     

  Tuire et al. ([@B51])          Yes                                                 Yes                                                                   Yes                    7                                Median: 24\               170                                     Not reported^b^                                              Not reported   2--41 y (range)
                                                                                                                                                                                                                   (range: 21--29)                                                                                                                               

  Valdimarsson et al. ([@B52])   Yes                                                 (?)                                                                   No                     13                               Median: 23.7\             17                                      Median: 23.6\                                                *p* = NS       8 y and 9 y (medians for groups) with 4--14 y (range)
                                                                                                                                                                                                                   (range: 17--29)                                                   (range: 19--30)                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mahadev et al. ([@B36]) reported body mass index categories (not shown). Although body mass index was associated with villous atrophy in univariate analysis (p = 0.014), it proved to be independent of histology after adjustment for covariates (p = NS for all categories).

The number of patients were not reported separately for atrophy and recovery groups.

*Values were given by Marsh 0 and 1--2 separately. (?) indicates uncertainty. CeD, celiac disease; GFD, gluten-free diet; m, month; min, minimum; NS, non-significant; Q~1~-Q~3~, 25% and 75% quartiles; SD, standard deviation; y, year*.

### Malignant Tumors and Other Co-morbid Conditions

Four studies reported the overall rate of malignant tumors during follow-up (Kaukinen et al., [@B22]; Tuire et al., [@B51]; Pekki et al., [@B41], [@B40]), two of which performed univariate analysis where event rates were 4.5 vs. 5.1% (*p* = 0.762) and 11.3 vs. 6% (*p* = 0.116) with PVA vs. MR, respectively (Pekki et al., [@B41], [@B40]) ([Table 10](#T10){ref-type="table"}).

###### 

Malignant tumors in celiac patients with persistent villous atrophy and mucosal recovery.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                  **Only strict GFD?**   **Malignant tumors**                                   **N**^****0****^ **of cases/Total**\   **Statistics**       **Timing of follow-up biopsy**\                              **Follow-up period**                                      
                                                                                                           **(%)**                                                     **(from diagnosis of CeD)**                                                                                            
  -------------------------- ---------------------- ------------------------------------------------------ -------------------------------------- -------------------- ------------------------------------------------------------ --------------------------------------------------------- --------------------------------------------------------------------------------
  Kaukinen et al. ([@B22])   Yes                    Any malignant tumor[^a^](#TN32){ref-type="table-fn"}   3 cases/13 pts\                        0 cases/18 pts\      Not reported                                                 8 y and 10 y (medians for groups) (range: 3--30 y)        4--5 years from follow-up biopsy
                                                                                                           (23.1)                                 (0.0)                                                                                                                                       

  Lebwohl et al. ([@B28])    No                     Any lymphoma                                           41 cases/4317 pts\                     12 cases/3308 pts\   **HR** **=** **2.26\                                         1.3 (median) (range: 6 m−5 y)                             10.6 y (median) from diagnosis of CeD and 8.9 y (median) from follow-up biopsy
                                                                                                           (0.9)                                  (0.4)                (CI: 2.28--4.34)**[^**d**^](#TN35){ref-type="table-fn"}                                                                

                                                    Any non-Hodgkin lymphoma                               34 cases/4317 pts\                     8 cases/3308 pts\    **HR** **=** **2.82**\                                                                                                 
                                                                                                           (0.8)                                  (0.2)                **(CI: 1.29--6.17)**[^**d**^](#TN35){ref-type="table-fn"}                                                              

                                                    Any B-cell lymphoma                                    4 cases/4317 pts\                      3 cases/3308 pts\    **HR** **=** **0.97**\                                                                                                 
                                                                                                           (\<0.1)                                (\<0.1)              **(CI: 0.21--4.49)**[^**d**^](#TN35){ref-type="table-fn"}                                                              

                                                    Any T-cell lymphoma                                    10 cases/4317 pts\                     2 cases/3308 pts\    **HR** **=** **3.51**\                                                                                                 
                                                                                                           (0.2)                                  (\<0.1)              **(CI: 0.75--16.34)**[^**d**^](#TN35){ref-type="table-fn"}                                                             

  Pekki et al. ([@B41])      No                     Any malignant tumor                                    9 cases/200 pts\                       14 cases/276 pts\    *p* = 0.762                                                  1 y                                                       8 y (median) from diagnosis of CeD
                                                                                                           (4.5)                                  (5.1)                                                                                                                                       

  Pekki et al. ([@B40])      No                     Any malignant tumor[^b^](#TN33){ref-type="table-fn"}   8 cases/71 pts\                        8 cases/134 pts\     *p* = 0.116                                                  1 y                                                       5 y (median) from diagnosis of CeD
                                                                                                           (11.3)                                 (6.0)                                                                                                                                       

                                                    Any lymphoma                                           1 case/71 pts\                         2 cases/134 pts\     *p* = 0.968                                                                                                            
                                                                                                           (1.4)                                  (1.5)                                                                                                                                       

  Tuire et al. ([@B51])      Yes                    Any malignant tumor[^c^](#TN34){ref-type="table-fn"}   0 cases/7 pts\                         4 cases/170 pts\     Not reported                                                 7 y, 9 y, and 10 y (medians for groups) (range: 2-41 y)   From diagnosis of CeD until follow-up biopsy
                                                                                                           (0.0)                                  (2.4)                                                                                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Multivariate analyses are highlighted with bold.

Cases included T-cell lymphoma, small bowel adenocarcinoma, and carcinoid tumor;

Cases included the uterus, breast, lung, pancreas, urinary bladder, and prostate tumors; lymphomas, and sarcomas.

Cases included breast, uterine, and prostate cancer; and lymphoma.

*The analysis was adjusted for age, sex, year of follow-up biopsy, education, and duration of celiac disease at the time of follow-up biopsy. CeD, celiac disease; CI, confidence interval; GFD, gluten-free diet; HR, hazard ratio; pts, patients; m, month; y, year*.

Incidence of lymphomas was 1.4 vs. 1.6% (*p* = 0.968) with PVA vs. MR in univariate analysis (Pekki et al., [@B41]). In a registry analysis, PVA had an adjusted HR of 2.26 (CI: 1.18--4.34) for the overall rate of lymphomas, being true for the subgroup of non-Hodgkin lymphomas but not for the subset of T-cell lymphomas (Lebwohl et al., [@B28]) ([Table 10](#T10){ref-type="table"}).

Sporadic records concerned other co-morbid conditions. Cardiovascular diseases including heart failure and atrial fibrillation (Lebwohl et al., [@B26]), hypertension (Mahadev et al., [@B36]), serious infections (including sepsis, streptococcal, pneumococcal, influenza, herpes zoster, and *Clostridium difficile* infections) (Emilsson et al., [@B13]) and adverse pregnancy outcomes (Lebwohl et al., [@B30]) were not influenced by follow-up histology. However, there was a significant reduction in the frequency of respiratory and dermatological diseases (Pekki et al., [@B40]) and in the rate of elevated aspartate and alanine transaminase levels with MR (Mahadev et al., [@B36]). In contrast, MR predisposed to developing anxiety and depression (Ludvigsson et al., [@B34]) as well as epilepsy (Kurien et al., [@B25]). The effect of follow-up histology on immune-mediated co-morbidities including dermatitis herpetiformis is severely understudied (Valdimarsson et al., [@B52]; Tuire et al., [@B51]; Mahadev et al., [@B36]).

### All-Cause and Cause-Specific Mortality

Four studies reported all-cause mortality during follow-up (Kaukinen et al., [@B22]; Rubio-Tapia et al., [@B44]; Lebwohl et al., [@B27]; Pekki et al., [@B41]), two of which adjusted the analysis for significant co-variates (Rubio-Tapia et al., [@B44]; Lebwohl et al., [@B27]). In this regard, MR seemed to be protective in a small retrospective study with a HR of 0.13 (CI: 0.02--1.06) (Rubio-Tapia et al., [@B44]), not confirmed by a nationwide registry analysis (HR = 1.0, CI: 0.86--1.19 for PVA) (Lebwohl et al., [@B27]). In the latter study, results were consistent on cardiovascular, tumor-related and respiratory deaths: the beneficial effect of MR was not confirmed (Lebwohl et al., [@B27]) ([Table 11](#T11){ref-type="table"}).

###### 

Studies reporting on mortality in celiac patients with persistent villous atrophy and mucosal recovery.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                     **Only strict GFD?**   **Mortality**     **N**^****0****^ **of cases/Total**\                           **Statistics (atrophy vs. recovery)**                          **Timing of follow-up biopsy**\                                                                         **Follow-up period**                                 
                                                                         **(%)**                                                                                                                       **(from diagnosis of CeD)**                                                                                                                                  
  ----------------------------- ---------------------- ----------------- -------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------
  Kaukinen et al. ([@B22])      Yes                    All-cause         2 cases/13 pts\                                                1 case/18 pts\                                                 Not reported                                                                                            8 y and 10 y (medians for groups) (range: 3--30 y)   4--5 years from follow-up biopsy
                                                                         (15.4)                                                         (5.6)                                                                                                                                                                                                                       

  Pekki et al. ([@B41])         No                     All-cause         10 cases/71 pts\                                               12 cases/134 pts\                                              *p* = 0.259                                                                                             1 y                                                  8 y (median) from diagnosis of CeD
                                                                         (14.1)                                                         (9.0)                                                                                                                                                                                                                       

  Rubio-Tapia et al. ([@B44])   No                     All-cause         10 cases/117 pts\                                              1 case/124 pts\                                                **HR** **=** **0.13**\                                                                                  Min: 5 m                                             10 y from diagnosis of CeD
                                                                         (8.5)                                                          (0.8)                                                          **(CI: 0.02--1.06)**[^**a**^](#TN36){ref-type="table-fn"}\                                                                                                   
                                                                                                                                                                                                       ***p*** **=** **0.06 (favors recovery)**                                                                                                                     

  Lebwohl et al. ([@B27])       No                     All-cause\        Unknown number of 3,317 pts[^b^](#TN37){ref-type="table-fn"}   Unknown number of 4,331 pts[^b^](#TN37){ref-type="table-fn"}   HR = 1.37 (CI: 1.16--1.62)[^c^](#TN38){ref-type="table-fn"} (favors recovery); **HR** **=** **1.01**\   1.3 (median) (range: 6 m−5 y)                        11.5 y (median) from diagnosis of CeD and 9.9 y (median) from follow-up biopsy
                                                       Cardiovascular\                                                                                                                                 **(CI: 0.86--1.19) after adjustment**[^**d**^](#TN39){ref-type="table-fn"}                                                                                   
                                                       Malignancy\                                                                                                                                                                                                                                                                                                  
                                                       Respiratory                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                       **HR** **=** **1.03**\                                                                                                                                       
                                                                                                                                                                                                       **(CI: 0.76-1.38)**[^**d**^](#TN39){ref-type="table-fn"}                                                                                                     

                                                                                                                                                                                                       **HR** **=** **1.20**\                                                                                                                                       
                                                                                                                                                                                                       **(CI: 0.88-1.66)**[^**d**^](#TN39){ref-type="table-fn"}                                                                                                     

                                                                                                                                                                                                       **HR** **=** **0.78**\                                                                                                                                       
                                                                                                                                                                                                       **(CI: 0.41-1.48)**[^**d**^](#TN39){ref-type="table-fn"}                                                                                                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Multivariate analyses are highlighted with bold.

The analysis was adjusted for age and gender.

Total mortality of the cohort of patients was 8.0%.

The analysis was unadjusted.

*The analysis was adjusted for age, gender, calendar period of diagnosis, education level, and length of follow-up. CeD, celiac disease; CI, confidence interval; GFD, gluten-free diet; HR, hazard ratio; pts, patients; m, month; y, year*.

Discussion {#s4}
==========

Summary of Findings
-------------------

Whether the follow-up biopsy in asymptomatic CeD is needed is uncertain, and, to date, no systematic review has addressed this question. Achieving MR is a desirable goal of treatment; however, findings of reports which investigated its beneficial effects on disease course are inconsistent. In line with our previous findings, MR rates ranged from 9 to 97% across the studies included (Szakacs et al., [@B48]). The fact that a considerable fraction of CeD patients does not achieve MR underlines the importance of investigating the potential prognostic role of follow-up histology.

One important conclusion of this review is that many asymptomatic patients do not achieve MR, and vice versa, many symptomatic patients do achieve MR. Analogously, MR cannot guarantee the symptoms to disappear, whereas PVA is often associated with persisting symptoms, even on a long-term follow-up exceeding 1 year ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). Persisting symptoms may indicate poor dietary adherence (Abdulkarim et al., [@B1]; Leffler et al., [@B31]; Haere et al., [@B17]) or gluten-independent food intolerance (Carroccio et al., [@B6]) but other diseases, such as pancreatic insufficiency or small intestinal bacterial overgrowth, might be in the background (Fine et al., [@B15]). Noteworthy that a few studies included patients with questionable adherence to gluten-free diet, although a top-quality study established a straight relationship between persisting symptoms and PVA in co-variate-adjusted analysis of patients with good adherence (Carroccio et al., [@B6]). Studies used various definitions for assessing symptoms; some did not report how symptoms were specified at all. Although a smaller study favored MR regarding a set of individual symptoms (Carroccio et al., [@B6]), the most extensive study including only symptomatic patients found significant associations in univariate analysis (with an unexpected inverse association between PVA and heartburn). Interestingly, all associations proved to be non-significant after adjusting for co-variates (Mahadev et al., [@B36]). Self-reporting of subjective complaints may contribute to the discrepant results. Use of symptom scales (Svedlund et al., [@B47]) provided a comparable measure with homogenous results: none of the studies attributed higher scores for those patients with PVA compared to those with MR ([Table 4](#T4){ref-type="table"}). The same association applies to quality of life; however, based on small sets of patients ([Table 4](#T4){ref-type="table"}). Altogether, the diagnostic accuracy of persisting symptoms seems insufficient for indicating a follow-up biopsy. Evidence coming from the two prospective studies is not enough to decide whether PVA precisely predicts the long-term persistence of symptoms (Pekki et al., [@B41], [@B40]) ([Table 4](#T4){ref-type="table"}).

PVA appears to be associated with radiologically detected metabolic bone disease in univariate analysis ([Table 5](#T5){ref-type="table"}), which translates into an increased risk of hip fractures (as an independent predictor) but not into that of the overall fractures ([Table 6](#T6){ref-type="table"}). Calcium malabsorption (Fang et al., [@B14]) together with vitamin D deficiency (Valdimarsson et al., [@B52]; Fang et al., [@B14]) are likely to be causative factors. Length of follow-up (not standardized among studies) may be insufficient for restoring bone mineral density (Pekki et al., [@B41]), especially in those with severe bone impairment at diagnosis. Body mass index, as an important co-variate, seems to be independent of mucosal status ([Table 9](#T9){ref-type="table"}).

Laboratory studies describing vitamin and mineral levels tend to recover on an adequate diet. Patients on a long-term strict gluten-free diet may suffer from vitamin deficiencies (Hallert et al., [@B19], [@B20]), this phenomenon might be explained by the vitamin- and micronutrient-poor nature of the gluten-free diet as compared to a balanced gluten-containing diet (Thompson, [@B49]). None of the studies adjusted for dietary adherence and vitamin supplementation which might counteract malabsorption and masked the effects of PVA. Variability in clinical and histological severity at diagnosis might delay villous restitution, thereby affecting vitamin status (not taken into account in the studies) (Kemppainen et al., [@B23]). Besides, improvement of histology might lag behind the recovery of laboratory values (Pekki et al., [@B41]), although the length of follow-up exceeded 1 year in all studies ([Table 7](#T7){ref-type="table"}).

Regarding mortality, the adjusted HRs calculated in the individual studies attributed a neutral effect to MR and PVA ([Table 11](#T11){ref-type="table"}) (Rubio-Tapia et al., [@B44]; Lebwohl et al., [@B27]). Findings were similar on malignant tumors, except in certain lymphoproliferative diseases based on an extensive registry analysis (noteworthy that data were not adjusted for dietary adherence) (Lebwohl et al., [@B28]). A possible explanation could be that the increment in rates of mortality and tumors with PVA was counteracted by a decreased risk of ovarian, endometrial and breast cancer, likely due to lower body weight and/or earlier menopause (Ludvigsson et al., [@B35]; Lebwohl et al., [@B27]).

Strengths and Limitations
-------------------------

Our study has several strengths. The question we raised is unique without known previous systematic review. We carried out an extensive systematic search with high coverage of patient-important outcomes in a transparent manner by independent (and pre-trained) investigators with good inter-rater agreement. The quality of the included papers was rigorously assessed.

Although the amount of data presented in the tables would be enough for meta-analytical aggregations that we intended to do initially (as declared in the protocol of the work, see the PROSPERO record); finally, our team decided not to do so because of several concerns. The decision-making algorithm is presented in [Figure 2](#F2){ref-type="fig"}.

![Decision-making algorithm. Based on several arguments, we decided not to perform a meta-analysis.](fphys-10-01408-g0002){#F2}

We are aware that the evidence suffers from several limitations. (1) Most studies did not recruit patients immediately after the diagnosis of CeD (29/31, 94%), did not take the follow-up biopsy after recruitment (23/31, 74%) and did not assess the disease course prospectively. (2) Although the diagnosis of CeD was mainly biopsy-proven, only two papers included newly diagnosed cases and observed them longitudinally until the follow-up biopsy. (3) Details of histological sampling and processing (e.g., sampling site, number of tissue samples, orientation, staining) were not consistently reported across papers, while the procedures often deviated from recent gold standards (e.g., samples were taken from the jejunum, histological classification systems were not specified). Similarly, the definition of villous atrophy varied across the studies. (4) Observational studies are vulnerable to bias: in registry analyses, data of the deceased were often missing (survivorship bias), attendance to regular control visits was incomplete (attrition bias), baseline differences between groups of patients with MR and those with PVA were rarely balanced with co-variate-adjusted analyses (selection bias), study samples were not taken consistently from the general CeD population with consecutive recruitment (selection bias), and investigators assessing the outcomes were rarely blind to mucosal status (performance bias, detection bias). (5) Most evidence came from studies focusing on adults while an inverse association between age and rate of MR is well-known (Szakacs et al., [@B48]). (6) A strict gluten-free diet was not a criterion in several studies, the length of diet varied. (7) Publication bias cannot be reliably assessed in systematic reviews.

Conclusion {#s5}
==========

Implications for Practice
-------------------------

The results of publications on the prognostic role of follow-up histology (that is, MR and PVA) are not in agreement. Some adverse outcomes (e.g., persistent symptoms and metabolic bone disease) may be more common with PVA; however, achieving MR alone cannot guarantee a favorable clinical course to our current knowledge. The question as to whether taking a follow-up biopsy is beneficial has remained a matter of debate.

Implications for Research
-------------------------

With a view to the future, prospective cohort studies are urged to be organized to collect decisive evidence on the prognostic role of follow-up histology.
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SF-36

:   36-Item Short Form Health Survey

CeD

:   celiac disease

GSRS

:   Gastrointestinal Symptom Rating Scale

HR

:   hazard ratio

IBS

:   irritable bowel syndrome

MR

:   mucosal recovery

NS

:   non-significant

OR

:   odds ratio

PGWB

:   Psychological General Well-Being Index

PVA

:   persistent villous atrophy.
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